FRα Antibody Drug Conjugate Scoring via Optical Density Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing a cancer patient's response to therapy involving anti-FRα antibody-drug conjugates are subjective and prone to variability, lacking objectivity and repeatability.
Innovation Solution
A computer-based method that determines a predicted efficacy score by analyzing the optical density of membrane and cytoplasm staining in tissue samples using a diagnostic antibody linked to a dye, which targets the FRα protein on cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If visual assessment by pathologists is used to score cancer patient response, then the assessment can be performed with current standard techniques, but the scoring is prone to variability and subjectivity
Solution Approach 1:
The patent replaces the mechanical/visual assessment system used by pathologists with an automated image analysis system. The system uses digital images of tissue samples processed through algorithms that objectively quantify staining intensity and cell morphology, eliminating human subjectivity while maintaining the ability to assess patient response to anti-FRα ADC therapy.
Solution Approach 2:
The patent creates a digital copy of the tissue sample images and analyzes these copies using computational methods. Instead of directly observing and scoring tissue sections, the system works with digital representations that can be repeatedly measured without degradation, ensuring consistent and reproducible scoring results.
2Reliability
If visual assessment by pathologists is used, then the method is relatively simple, but it lacks objectivity and repeatability
Solution Approach 1:
The patent substitutes manual visual assessment with automated computational analysis. The system processes digital images through programmed algorithms that objectively measure staining intensity, cell density, and morphological features, providing reliable and repeatable results that do not vary between different assessors or over time.
Solution Approach 2:
The image analysis system is designed to automatically perform the scoring function without requiring skilled pathologists. The automated algorithms independently analyze tissue images, quantify staining patterns, and generate scores that can be consistently reproduced, making the system self-sufficient and eliminating dependency on human expertise.
3Adaptability or versatility
If FRα expression is used as a biomarker, then it can identify tumor regions and predict therapy response, but the distribution of FRα expression is limited to specific tissue types
Solution Approach 1:
The patent changes the approach from relying on high FRα expression levels to detecting FRα expression patterns and their spatial distribution within tissues. The image analysis system can identify FRα-positive cells even at lower expression levels by analyzing staining patterns, cell morphology, and tissue architecture, thereby expanding the applicability of FRα as a biomarker across different cancer types.
Solution Approach 2:
The patent shifts focus from the overall quantity of FRα expression to the local distribution and pattern of FRα staining within tissue sections. By analyzing the spatial arrangement, intensity variations, and cellular context of FRα expression, the system can identify tumor regions and predict therapy response even when FRα expression is heterogeneous or limited to specific areas.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a repeatable and objective score that predicts a cancer patient's response to anti-FRα ADC therapy, enabling more accurate treatment recommendations.
Implementation Method 1
A tissue sample is immunohistochemically stained using a dye linked to a diagnostic antibody that binds to the FRα protein on the cancer cells in the tissue sample
Implementation Method 2
determining a predicted efficacy score based on the optical density of membrane and, optionally, cytoplasm staining, by a dye linked to a diagnostic antibody
Data Source
AI summary
A method for predicting the efficacy of an antibody drug conjugate (ADC) therapy involves determining the mean optical density (OD) of membrane and optionally cytoplasm staining of each cancer cell in a whole slide image. A diagnostic antibody to which a dye is linked targets the same folate receptor alpha protein as does the ADC antibody. Statistical operations are performed on the OD of staining, such as computing the median, absolute deviation, difference in OD of membrane and cytoplasm staining, percentage of cells a minimum OD, or the sum of minimally stained cells plus insufficiently stained cells near stained cells. For example, a zero, high or low ADC dosage is recommended based on whether median OD falls below, between or above two OD thresholds, respectively. The upper and lower OD thresholds are correlated to responses of training patients treated with the ADC and whose stained cancer tissue has been analyzed.